Same monitoring rules, same dose-timing considerations, same red flags
The current state of the market is being held back by several forces

Tirzepatide Read the full profile Receptors activated (GIP + GLP-1 (dual)) Molecular weight (4,813.45 Da) Half-life (~5 days) Average weight loss (SURMOUNT-5, 72 wk) (~20%) Typical starting dose (2.5 mg/week) Typical maintenance dose (515 mg/week) Titration schedule (+2.5 mg every 4 weeks) Given as a weekly shot Available forms (Injection only) FDA-approved (Mounjaro/Zepbound) Brand-name price (no insurance) ($1,000+/month) Compounded price (where available) ($125$278/month) Shared GI side effects (nausea, etc.) Approved for sleep apnea Semaglutide Read the full profile Receptors activated (GLP-1 only) Molecular weight (4,113.64 Da) Half-life (~7 days) Average weight loss (STEP 1, 68 wk) (~15%) FDA-approved for cardiovascular risk reduction Typical starting dose (0.25 mg/week) Typical maintenance dose (2.4 mg/week) Titration schedule (+0.250.5 mg every 4 weeks) Given as a weekly shot Available forms (Injection or oral tablet (Rybelsus)) FDA-approved (Ozempic/Wegovy) Brand-name price (no insurance) ($1,000+/month) Compounded price (where available) ($99$178/month) Shared GI side effects (nausea, etc.) Our top-rated vendor Our rankings are based solely on third-party lab testing rigor, COA transparency, and pricing no paid placements, no affiliate influence

Further research is under way to characterize the role of incretin mimetics in overweight or obese patients without diabetes
Phase 2 data showed the 8mg combined group achieved 22.8% mean weight reduction at 48 weeks, which is only 1.4 percentage points less than the 12mg group